This site is intended only for healthcare professionals resident in the United Kingdom

Other indications

Fragmin® is a low molecular weight heparin with a number of indications which include the extended treatment of Cancer Associated Thrombosis in solid tumour patients

Unstable Angina and NSTEMI: Risk Factors

If UA and NSTEMI are untreated after a firm diagnosis, the prognosis is poor and mortality high, particularly in patients with myocardial damage¹

•Appropriate triage, risk assessment and timely use of acute pharmacological and invasive interventions is critical in preventing future cardiovascular events (MI, stroke, repeat revascularisation and death)

References

Unstable angina and NSTEMI: early management. Clinical guideline [CG94]. Updated November 2013. Available at: https://www.nice.org.uk/guidance/cg94/resources/unstable-angina-and-nstemi-early-management-pdf-975749355205

*Including, but not limited to: congestive cardiac failure (NYHA class III or IV), acute respiratory failure or acute infection, who also have a predisposing risk factor for VTE such as age over 75 years, obesity, cancer or previous history of VTE.~
†In patients with chronic renal insufficiency or acute renal failure.

Fragmin^® Prescribing Information

PP-FRA-GBR-0160. June 2019